ICCC - Rasio kapitalisasi pasar marang pendapatan ImmuCell Corp.
Rising demand for First Defense and capacity expansion have led to increased B2B sales margins for ImmuCell Corporation (ICCC). The P/S multiple trend clearly demonstrates the market valuation of revenue, while the 3.00 metric confirms the current level. ImmuCell Corporation (ICCC) facilitates the reduction of antibiotic use in livestock farming, maintaining its leadership in the preventive therapy niche through unique patents that protect the business from pricing pressure.
Rincian metrik lan analitis perusahaan ImmuCell Corp. (ICCC)
High capacity utilization at ImmuCell Corporation for the production of veterinary drugs drives the price-to-sales ratio dynamics. This indicator reflects the market value of the business relative to its annual revenue, allowing for the identification of asset overheating. The calculation is performed by dividing the company's market capitalization by total sales, resulting in the current value of 3.00. This helps investors assess the monetization efficiency of production assets and determine a safe entry threshold for a position.
